The total value of the transdermal drug delivery systems market was USD 4.2 billion in 2023, and it will power at a compound annual growth rate of 4.7% by the end of this decade, to touch USD 5.8 billion in 2030.
The sector is mostly driven by the rising incidence of chronic illnesses, and for the same, a conservative drug delivery system is weaker than required due to hepatic first-pass metabolism. What is meant by this is that, when utmost oral drugs enter the liver, they are mostly digested before reaching the targeted tissue, therefore bringing about insufficient efficacy.
More than one billion people at a global level smoke cigarette, with incidence continuing to be high in spite of surveillance, educational, and supply restriction efforts on the international and national levels.
This factor is driving the requirement for transdermal nicotine patches for ages. If the reports are to be believed, as opposed to a placebo administered for a year, nicotine patches are 50–60% more successful in helping individuals give up cigarettes.
North American transdermal drug delivery systems market is the leader. The expansion in this continent is chiefly driven by patent expirations, letting more businesses to enter the industry with generic alternatives of these devices.
Also, the relaunch of previously failed drugs for subcutaneous delivery and the vast spending by the stalwarts on related research and development are key reasons for the substantial share seized by this region.
Due to the growing incidence of chronic illnesses all over the world, the demand for transdermal drug delivery systems is on the rise. This trend will continue in the years to come as well.
